Substantial medicare savings may result if insurers cover 'artificial pancreas' sooner for diabetes patients

Health Affairs

Volumn 31, Issue 8, 2012, Pages 1822-1829

  O'Grady, Michael J ^a   John, Priya ^b   Winn, Aaron ^c  

^a Health Policy Center   (United States)

^b Tufts Medical Center ^*

^c TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE;

ARTICLE; ARTIFICIAL PANCREAS; BLOOD GLUCOSE MONITORING; COST CONTROL; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH INSURANCE; HEART FAILURE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MEDICARE; STROKE;

ADULT; COST SAVINGS; DIABETES MELLITUS; HUMANS; INSURANCE COVERAGE; INSURANCE, HEALTH; MEDICARE; MIDDLE AGED; MODELS, THEORETICAL; PANCREAS, ARTIFICIAL; UNITED STATES;

EID: 84866318089     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2011.1052     Document Type: Article

References (17)

1. Authors' analysis, using the definition of diabetes used by the Centers for Medicare and Medicaid Services to risk-adjust Medicare Advantage payments. CMS.gov. Risk adjustment [Internet]. Baltimore (MD): Centers for Medicare and Medicaid Services; [last modified 2012 Apr 25; cited 2012 Jul 5]. Available from: http://www.cms.gov/Medicare/ Health-Plans/MedicareAdvtg SpecRateStats/Risk_adjustment .html
2. Lifetime benefits and costs of intensive therapy as practiced in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group. JAMA. 1996;276(17):1409-15.
3. Chico A, Vidal-Ríos P, Subirà M, Novials A. The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemia in patients with type 1 and type 2 diabetes but is not better than frequent capillary glucose measurements for improving metabolic control. Diabetes Care. 2003; 26(4):1153-7.
4. Huang ES, O'Grady M, Basu A, Winn A, John P, Lee J, et al. The costeffectiveness of continuous glucose monitoring in type 1 diabetes. Diabetes Care. 2010;33(6):1269-74.
5. Kowalski AJ. Can we really close the loop and how soon? Accelerating the availability of an artificial pancreas: a roadmap to better diabetes outcomes. Diabetes Technol Ther. 2009;11(Suppl 1):S113-9.
6. El-Khatib FH, Russell SJ, Nathan DM, Sutherlin RG, Damiano ER. A bihormonal closed-loop artificial pancreas for type 1 diabetes. Sci Transl Med. 2010;2(27):27ra27.
7. Hovorka R, Allen JM, Elleri D, Chassin LJ, Harris J, Xing D, et al. Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial. Lancet. 2010; 375(9716):743-51.
8. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352(9131):837-53.
9. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329(14):977-86.
10. Food and Drug Administration. FDA's Critical Path Initiative [Internet]. Silver Spring (MD): FDA; [last updated 2011 Jan 20; cited 2012 July 12]. Available from: http://www .fda.gov/ScienceResearch/Special Topics/CriticalPathInitiative/ ucm076689.htm
11. Food and Drug Administration [Internet]. Silver Spring (MD): FDA. Press release, FDA outlines flexible approaches for artificial pancreas system clinical trials, product approvals; 2011 Dec 1 [cited 2012 Jun 27]. Available from: http:// www.fda.gov/NewsEvents/News room/PressAnnouncements/ ucm281815.htm
12. Our analysis of the 2008 fee-forservice Medicare claims with a diagnosis code for diabetes (see Note 1) indicated that 912,280 feefor-service beneficiaries received services with the International Classification of Diseases, Ninth Revision (ICD-9), code 25001 (for " Diabetes Mellitus without mention of complication, Type I (juvenile type), not stated as uncontrolled" ) and 215,740 fee-for-service beneficiaries received services with the ICD-9 code 25003 (for " Diabetes Mellitus without mention of complication, Type I (juvenile type), uncontrolled" ). Given that the same patient might be coded as uncontrolled at one point in the year and controlled at another, we hesitated to simply add the two numbers together. If the only claim with one of these codes was for screening the patient, we did not count the beneficiary as having diabetes.
13. Huang ES, Basu A, O'Grady M, Capretta JC. Projecting the future diabetes population size and related costs for the U.S. Diabetes Care. 2009;32(12):2225-9.
14. Juvenile Diabetes Research Foundation. Artificial pancreas project [Internet]. New York (NY): JDRF; [cited 2012 Jul 5]. Available from: http:// www.artificialpancreasproject.com/ about/insurance.html
15. The top 25 health insurance companies [Internet]. US News and World Report [serial on the Internet]. 2012 [cited 2012 Jul 5]. Available from: http://health.usnews .com/health-plans/nationalinsurance-companies
16. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008;359:1464-76.
17. To access the Appendix, click on the Appendix link in the box to the right of the article online